TRIB Quote, Financials, Valuation and Earnings

Akari Therapeutics PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat Akari Therapeutics PLC's return on equity of --.

Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2265.56%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 6053.85%. Given that Akari Therapeutics PLC has higher upside potential than Trinity Biotech PLC, analysts believe Akari Therapeutics PLC is more attractive than Trinity Biotech PLC.

Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.306%.

Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is lower than Akari Therapeutics PLC's net income of -$3.7M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.13x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2265.56%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1608.94%. Given that Trinity Biotech PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Trinity Biotech PLC is more attractive than Biodexa Pharmaceuticals PLC.

Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.

Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.13x versus 1.09x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of -170.14%. Trinity Biotech PLC's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2265.56%. On the other hand Cellectis SA has an analysts' consensus of $5.60 which suggests that it could grow by 297.16%. Given that Trinity Biotech PLC has higher upside potential than Cellectis SA, analysts believe Trinity Biotech PLC is more attractive than Cellectis SA.

Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.107, suggesting its more volatile than the S&P 500 by 210.711%.

Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Cellectis SA quarterly revenues of $10.7M. Trinity Biotech PLC's net income of -$4.8M is higher than Cellectis SA's net income of -$18.1M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.13x versus 2.89x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.

Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2265.56%. On the other hand DBV Technologies SA has an analysts' consensus of $18.41 which suggests that it could grow by 96.89%. Given that Trinity Biotech PLC has higher upside potential than DBV Technologies SA, analysts believe Trinity Biotech PLC is more attractive than DBV Technologies SA.

Trinity Biotech PLC has a beta of 0.861, which suggesting that the stock is 13.871% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.

Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than DBV Technologies SA quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.13x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.